MGC Pharmaceuticals Limited ASX Trading Halt (7616X)

TIDMMXC

RNS Number : 7616X

MGC Pharmaceuticals Limited

06 May 2021

 
 6 May 2021   MGC Pharmaceuticals Ltd 
  ASX Code:       ASX Trading Halt 
     MXC 
  LSE Code: 
     MXC

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company') advises that trading in the shares of the Company have been halted on the Australian Securities Exchange ("ASX") effective from Thursday, 6 May 2021. The halt was requested by the Company pending the release of an announcement by the Company in relation to further findings on ArtemiC(TM) .

The trading halt will remain until the earlier of an announcement to the market regarding the above or the opening of trade on ASX on 10 May 2021.

Trading in the Company's ordinary securities will continue on LSE during this period.

. --Ends--

 
 MGC Pharmaceuticals Ltd    UK PR Tavistock - Tavistock 
  Roby Zomer                 Tim Pearson +44 7983118 502 
  CEO & Managing Director    Tim.Pearson@tavistock.co.uk 
  +61 8 6382 3390 
  info@mgcpharma.com.au 
 UK Broker - Turner Pope    Australian PR/IR Advisors - Media & Capital 
  Andy Thacker               Partners 
  info@TurnerPope.com        Rod Hinchcliffe (IR) +61 412 277 377 
                             Rod.Hinchcliffe@mcpartners.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGLGDURDGDGBL

(END) Dow Jones Newswires

May 06, 2021 02:31 ET (06:31 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jun 2024 to Jul 2024